Hide Transcript Show Transcript

Okay. Okay. Rolling again. So way this happened. Waas. I came up with 19. I knew about this drug, the protein about to have 90 days to stop the virus and lost. People have ideas but very unusual thing here. So we have mind He runs a regional Biocon here, and that's one of the few places me virus test the pirates. What did he my idea. Test team Using special equipment. Everything is kept very safe. They took the virus and they keeping the cells with my throughout that I had 19 when they added the virus makes so way actually have tested it way. No, it worked. We know that it works against the active virus in this cell, so that gives us it really big. It's not just a hope, but I mean, it's leaps forward in getting the, uh, drug to market, right? Yes. So I say, let's of people have ideas about what? Some of them you know, I've already been tested in patients with a lot of those drugs Have side effects, unfortunately, so here we have a drug that way. No. Doesn't have any side of next. We know that stopped the virus this test that we did. So we just now need to try humans to see. Got it. Okay, I will.

Advertisement UofL believes it's made breakthrough in COVID-19 treatment, works to fast-track approval Share Shares Copy Link Copy

University of Louisville researchers say they may have made a breakthrough in fighting the novel coronavirus.In the race to find a treatment, UofL says it has developed a technology believed to block SARS-CoV-2, the virus that causes COVID-19, from infecting human cells.They explained it this way: The technology is based on a piece of synthetic DNA, or an “aptamer,” which targets and binds with a human protein called nucleolin. Researchers said early tests show this aptamer may stop viruses, including novel coronavirus, from “hijacking” nucleolin to replicate inside the body. Coronavirus in Kentucky, Indiana: Tracking COVID-19 curve of cases, deaths They have used this same technology in clinical trials for cancer."What we found was this is a safe kind of drug. It had very few side effects and that's why we're so excited about the prospects of moving this forward as a treatment for coronavirus. We don't think there's going to be any serious side effects," Paula Bates, a University School of Medicine professor, said. Hear from Bates in the video player above.She said they know that it works against the actual virus in a cell-based model, so that gives them "really big hope" that it will work in patients, too.Bates, along with John Trent and Don Miller, discovered the aptamer. She then partnered with fellow researcher Kenneth Palmer, who conducted proof-of-concept experiments showing the aptamer was effective against the virus at doses previous research has shown to be safe in patients, a news release said.Now, the researchers want to fast-track development, including application to the Food and Drug Administration for approval to start treating patients seriously affected with COVID-19."We know how to make it. We believe it can be scaled up pretty quickly to be made available as needed. I think everybody in science and medicine is behind this so when people find something that works, once they've shown it works, things will move very quickly with the FDA getting approved hopefully, and with being able to manufacture enough so everybody can have it for treatment," Bates said.